AGEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 3月 2024 @ 04:59):

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States...

Stats
本日の出来高	3 681.00
平均出来高	3 980.00
時価総額	27.76M
EPS	$0 ( 2024-03-29 )
次の収益日	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-08	Mintz Steven	Sell	0	Common Stock, $0.0001 par value
2024-01-08	Mintz Steven	Sell	63 756	Option to Purchase Common Stock
2023-08-09	Renondin Jean-christophe	Sell	25 821	Option to Purchase Common Stock
2023-04-25	Juvenescence Ltd	Buy	756 429	Warrant to Purchase Common Stock
2023-03-14	Juvenescence Ltd	Sell	16 447 500	Common Stock

INSIDER POWER
-63.19
Last 97 transactions
Buy: 22 648 571 \| Sell: 17 037 050

AgeX Therapeutics Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

AgeX Therapeutics Inc 財務諸表

Annual	2023
収益:	$142 000
総利益:	$-29 000.00 (-20.42 %)
EPS:	$-13.72

FY	2023
収益:	$142 000
総利益:	$-29 000.00 (-20.42 %)
EPS:	$-13.72

FY	2022
収益:	$34 000.00
総利益:	$21 000.00 (61.76 %)
EPS:	$-9.89

FY	2021
収益:	$144 000
総利益:	$125 000 (86.81 %)
EPS:	$-0.230

Financial Reports:

No articles found.

AgeX Therapeutics Inc

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.